[Recent Progress in Novel Therapies for Non-Muscle Invasive Bladder Cancer].

Non-muscle invasive bladder cancer(NMIBC)accounts for about 70% of bladder cancers, with most patients treated by TURBT followed by intravesical therapy according to recurrence risk.BCG is effective but BCG-unresponsive cases often require cystectomy.Recently, novel therapies including immune checkpoint inhibitors, drug-delivery devices, and gene therapy have emerged.This chapter reviews recent and ongoing phase Ⅲ trials in BCG-naïve NMIBC.